Drugs that contain Somatropin Recombinant
1. Genotropin Preservative Free patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5501673 | PHARMACIA AND UPJOHN | Injection cartridge |
Apr, 2013
(11 years ago) | |
| US5435076 | PHARMACIA AND UPJOHN | Injection device |
Apr, 2013
(11 years ago) | |
| US5716338 | PHARMACIA AND UPJOHN | Dual-chamber type injection cartridge with bypass connection |
Feb, 2015
(9 years ago) | |
| US6152897 | PHARMACIA AND UPJOHN | Syringe |
Nov, 2018
(5 years ago) | |
Market Authorisation Date: 23 October, 1996
Treatment: NA
Dosage: INJECTABLE;INJECTION
GENOTROPIN PRESERVATIVE FREE family patents
2. Norditropin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5633352 | NOVO NORDISK INC | Biosynthetic human growth hormone |
May, 2014
(9 years ago) | |
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE;INJECTION
NORDITROPIN family patents
3. Norditropin Flexpro patents
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(6 years ago) | |
| US6716198 | NOVO NORDISK INC | Injection device |
Jun, 2021
(2 years ago) | |
| US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(10 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(14 days from now) | |
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 5 months from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Market Authorisation Date: 23 January, 2015
Treatment: Treatment of disorders responsive to growth hormone
Dosage: INJECTABLE;INJECTION
NORDITROPIN FLEXPRO family patents
4. Norditropin Nordiflex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(6 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6235004 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE;INJECTION
NORDITROPIN NORDIFLEX family patents
5. Nutropin Aq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5763394 | GENENTECH | Human growth hormone aqueous formulation |
Jun, 2015
(8 years ago) | |
Market Authorisation Date: 03 January, 2008
Treatment: NA
Dosage: INJECTABLE;INJECTION
NUTROPIN AQ family patents
6. Nutropin Aq Pen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5763394 | GENENTECH | Human growth hormone aqueous formulation |
Jun, 2015
(8 years ago) | |
Market Authorisation Date: 03 January, 2008
Treatment: NA
Dosage: INJECTABLE;INJECTION
NUTROPIN AQ PEN family patents
7. Nutropin Depot patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6051259 | GENENTECH | Composition for sustained release of human growth hormone |
Dec, 2012
(11 years ago) | |
| US5656297 | GENENTECH | Modulated release from biocompatible polymers |
Jul, 2014
(9 years ago) | |
| US5654010 | GENENTECH | Composition for sustained release of human growth hormone |
Aug, 2014
(9 years ago) | |
Market Authorisation Date: 22 December, 1999
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE;INJECTION
NUTROPIN DEPOT family patents
8. Saizen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5898030 | EMD SERONO | hGH containing pharmaceutical compositions |
Apr, 2016
(8 years ago) | |
Market Authorisation Date: 16 January, 2007
Treatment: NA
Dosage: INJECTABLE;INJECTION
SAIZEN family patents
9. Serostim patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5898030 | EMD SERONO | hGH containing pharmaceutical compositions |
Apr, 2016
(8 years ago) | |
Market Authorisation Date: 25 July, 1997
Treatment: NA
Dosage: INJECTABLE;INJECTION
SEROSTIM family patents
10. Zorbtive patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5898030 | EMD SERONO | hGH containing pharmaceutical compositions |
Apr, 2016
(8 years ago) | |
Market Authorisation Date: 01 December, 2003
Treatment: NA
Dosage: INJECTABLE;INJECTION
ZORBTIVE family patents